DE69917478D1 - Piperazine und piperidine derivate - Google Patents

Piperazine und piperidine derivate

Info

Publication number
DE69917478D1
DE69917478D1 DE69917478T DE69917478T DE69917478D1 DE 69917478 D1 DE69917478 D1 DE 69917478D1 DE 69917478 T DE69917478 T DE 69917478T DE 69917478 T DE69917478 T DE 69917478T DE 69917478 D1 DE69917478 D1 DE 69917478D1
Authority
DE
Germany
Prior art keywords
piperazine
piperidine derivatives
piperidine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69917478T
Other languages
English (en)
Other versions
DE69917478T2 (de
Inventor
P Toorop
W Feenstra
Der Heijden A Van
Johannes Mos
K Long
M Visser
G Kruse
Scharrenburg J Van
G Hf Toorop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duphar International Research BV
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69917478(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Publication of DE69917478D1 publication Critical patent/DE69917478D1/de
Application granted granted Critical
Publication of DE69917478T2 publication Critical patent/DE69917478T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE69917478T 1998-11-13 1999-11-10 Piperazine und piperidine derivate Expired - Lifetime DE69917478T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98203871 1998-11-13
EP98203871 1998-11-13
PCT/EP1999/008702 WO2000029397A1 (en) 1998-11-13 1999-11-10 New piperazine and piperidine compounds

Publications (2)

Publication Number Publication Date
DE69917478D1 true DE69917478D1 (de) 2004-06-24
DE69917478T2 DE69917478T2 (de) 2004-09-16

Family

ID=8234340

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69917478T Expired - Lifetime DE69917478T2 (de) 1998-11-13 1999-11-10 Piperazine und piperidine derivate

Country Status (28)

Country Link
US (1) US6780864B1 (de)
EP (1) EP1131308B1 (de)
JP (1) JP3638874B2 (de)
KR (1) KR100619465B1 (de)
CN (1) CN1225462C (de)
AR (1) AR021256A1 (de)
AT (1) ATE267183T1 (de)
AU (1) AU756470B2 (de)
BR (1) BR9915293B1 (de)
CA (1) CA2350137C (de)
CZ (1) CZ299774B6 (de)
DE (1) DE69917478T2 (de)
DK (1) DK1131308T3 (de)
DZ (1) DZ2934A1 (de)
ES (1) ES2217833T3 (de)
HK (1) HK1039489A1 (de)
HU (1) HUP0104922A3 (de)
IL (2) IL143028A0 (de)
MX (1) MXPA01004854A (de)
NO (1) NO318888B1 (de)
NZ (1) NZ511584A (de)
PL (1) PL193685B1 (de)
RU (1) RU2225406C2 (de)
SI (1) SI1131308T1 (de)
SK (1) SK285648B6 (de)
TW (1) TWI252230B (de)
UA (1) UA71590C2 (de)
WO (1) WO2000029397A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
NZ522116A (en) * 2000-05-12 2004-04-30 Solvay Pharmaceuticals B Piperazine and piperidine compounds that have partial agonism towards dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors
EP1284731A1 (de) * 2000-05-12 2003-02-26 Solvay Pharmaceuticals B.V. Verwendung von verbindungen mit kombinierter d2, 5-ht1a und alpha adrenoceptor agonistischer wirkung zur behandlung von zns-erkrankungen
BR0115297A (pt) * 2000-11-14 2003-08-26 Merck Patent Ges Mit Beschonkt Usos de antagonistas seletivos do receptor de dopamina d2 e agonistas do receptor 5-ht1a combinados
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
US6800648B2 (en) 2001-04-26 2004-10-05 Wyeth Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-1,6,9-trioxa-3-AZA-cyclopenta[a]naphthalen-2-one
US6743796B2 (en) * 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
ES2280602T3 (es) 2001-07-26 2007-09-16 Merck Patent Gmbh Uso de 2-(5-(4-fluorofenil)-3-piridilmetilaminometil)-cromano y sus sales fisiologicamente aceptables.
EP1336406A1 (de) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partieller Dopamin-D2 Rezeptoragonist plus Substanzen mit Serotonin- und/oder Noradrenalin inhibitorischer Aktivität
WO2004000837A1 (ja) * 2002-06-25 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. 新規なベンズオキサゾリノン誘導体
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
EP1595542A1 (de) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermale iontophoretische Verabreichung von Piperazinyl-2(3H)-benzoxazolon-Verbindungen
ATE440826T1 (de) 2004-05-27 2009-09-15 Ucb Pharma Sa Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
AR058022A1 (es) * 2005-08-22 2008-01-23 Solvay Pharm Bv Derivados de benzooxazoles, composiciones farmaceuticas y su uso para el tratamiento de desordenes del sistema nervioso.
JP2009504799A (ja) * 2005-08-22 2009-02-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ピペラジンおよびピペリジン誘導体のプロドラッグとしてのｎ−オキシド
US7750013B2 (en) 2005-08-22 2010-07-06 Solvay Pharmaceuticals, B.V. N-oxides as prodrugs of piperazine and piperidine derivatives
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
UY32935A (es) * 2009-10-12 2011-05-31 Abbott Healthcare Products Bv Polimorfos de pardoprunox
EP3503879A4 (de) 2016-08-26 2020-04-29 EXCIVA GmbH Zusammensetzung und verfahren dafür

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567884B1 (fr) 1984-07-19 1987-03-06 Roussel Uclaf Nouveaux derives de l'indole, leur preparation, leur application comme medicaments et les compositions les renfermant
EP0190472B1 (de) * 1984-12-21 1989-07-12 Duphar International Research B.V Arzneimittel mit antipsychotischer Wirkung
EP0189612B1 (de) * 1984-12-21 1992-11-04 Duphar International Research B.V Arzneimittel mit psychotroper Wirkung
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
IL114026A (en) 1994-06-08 1999-06-20 Lundbeck & Co As H 4-aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzo thiophenemethyl) piperidines tetrahydropyridines or piperazines and pharmaceutical compositions containing them
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
IL126187A0 (en) 1996-03-29 1999-05-09 Duphar Int Res Piperazine and piperidine compounds
EP0900792B1 (de) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten

Also Published As

Publication number Publication date
CN1225462C (zh) 2005-11-02
IL143028A0 (en) 2002-04-21
SK6492001A3 (en) 2001-10-08
CZ20011657A3 (cs) 2001-10-17
MXPA01004854A (es) 2005-07-25
SI1131308T1 (en) 2004-10-31
HK1039489A1 (en) 2002-04-26
EP1131308B1 (de) 2004-05-19
ATE267183T1 (de) 2004-06-15
JP2002530276A (ja) 2002-09-17
DK1131308T3 (da) 2004-06-28
WO2000029397A1 (en) 2000-05-25
DE69917478T2 (de) 2004-09-16
TWI252230B (en) 2006-04-01
DZ2934A1 (fr) 2004-03-15
NO318888B1 (no) 2005-05-18
UA71590C2 (en) 2004-12-15
CZ299774B6 (cs) 2008-11-19
EP1131308A1 (de) 2001-09-12
CA2350137C (en) 2008-04-22
NO20012339D0 (no) 2001-05-11
CA2350137A1 (en) 2000-05-25
PL193685B1 (pl) 2007-03-30
IL143028A (en) 2006-12-10
AR021256A1 (es) 2002-07-03
AU756470B2 (en) 2003-01-16
PL347635A1 (en) 2002-04-22
BR9915293A (pt) 2001-08-07
HUP0104922A2 (en) 2002-08-28
NO20012339L (no) 2001-05-11
AU1270900A (en) 2000-06-05
HUP0104922A3 (en) 2003-05-28
SK285648B6 (sk) 2007-05-03
BR9915293B1 (pt) 2011-11-01
RU2225406C2 (ru) 2004-03-10
CN1378540A (zh) 2002-11-06
KR100619465B1 (ko) 2006-09-05
JP3638874B2 (ja) 2005-04-13
ES2217833T3 (es) 2004-11-01
US6780864B1 (en) 2004-08-24
KR20010080995A (ko) 2001-08-25
NZ511584A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
ATE267183T1 (de) Piperazine und piperidine derivate
NO20023787D0 (no) Piperazin- og piperidinderivater
ATE305933T1 (de) Piperazin derivate
ATE407131T1 (de) Substituierte bipiperidine -zwischenverbindungen und deren derivate
BR9712037A (pt) Derivados de piperazina
DE69911378D1 (de) Fluorierte ionomere und verwendung davon
ATE353326T1 (de) Piperazin-derivate
AR028343A1 (es) Derivados de pirrolidina y piperidina
DK1198453T3 (da) N-(indolcarbonyl-)piperazinderivater
DE69903143D1 (de) Chromanon und thiochromanon derivate
ATE278695T1 (de) Piperidinderivate
ATE321042T1 (de) Piperazin-derivate
PT1283838E (pt) Compostos de piperazina e de piperidina
DE69903961D1 (de) Muscarinagonisten und antagonisten
ATE266637T1 (de) 3,3-biarylpiperidin- und 3,3- biarylmorpholinderivate
DE69916694D1 (de) 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on
ATE247105T1 (de) Antipsychotische 4-(1h-indolyl-1-yl)-1- substituierte piperidine derivate
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
DE69904738D1 (de) 2-phenylpyran-4-one derivate
DK0937458T3 (da) Pyrrolidin- og piperidinderivater
ATE362915T1 (de) Heterocyclische derivate und arzneistoffe
DE69926161D1 (de) Füllstoff und Pigment
NO992302D0 (no) Piperidin-derivater
PT1131308E (pt) Novos compostos de piperazina e piperidina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition